A Tulane surgeon says Louisiana insurers cover surgery more often than GLP-1s, and argues surgery costs less over a lifetime than taking the shots for life.
Recap by typeshit. Full story at KSNB.
General exercise advice aimed at GLP-1 users, shared on Facebook with no study or expert named in the material available.
Gilead takes global rights to the Shanghai biotech's program, led by HCXT-2001, an oral peptide that could compete with injected IBD drugs.
A Facebook promo for a podcast episode on the ripple effects of GLP-1 consumers across businesses. Few details beyond the pitch.
10:49
xitsnemox posts a short check-in from week 14 on oral Wegovy, two weeks after stepping up to the 25mg tablet. A personal account, not medical advice.
GLP-1 prescriptions rose 24% from 2018 to 2025 as surgery fell. Tulane's Dr. Shauna Levy says Louisiana insurers cover surgery more often than the drugs.
Novo's head of diabetes marketing discusses how the company is reaching patients and what it learned from the Wegovy pill rollout.
Loading…